A simple blood or urine test, known as a liquid biopsy, can give you and your doctor personalized, real-time insights into your cancer. This information can shed light on the best course of treatment for you.
How Exosome-Based Tests Work
Exosome Diagnostics’ tests collect genetic information by extracting exosomes from your urine or blood. Exosomes are messengers released by all living cells that contain RNA, DNA, and protein. Because exosomes contain information from living cells, exosome-based liquid biopsies in oncology provide a real-time snapshot of the entire tumor’s activity and enable detection of important changes in your disease.
Unlike tissue-based biopsies, Exosome Diagnostics’ tests do not require invasive surgical procedures and as such can be used for ongoing monitoring to detect real-time changes in disease.
Our Liquid Biopsies
Exosome Diagnostics is the developer of three liquid biopsies for non-small cell lung cancer and one liquid biopsy for prostate cancer. Learn more about these tests below.
In prostate cancer, liquid biopsies can provide key information about the aggressiveness of cancer and may allow patients to avoid unnecessary biopsies with little risk. By continuing to monitor disease progression, doctors can determine when further treatment may be necessary. If you have prostate cancer, ask your doctor about ExoDx Prostate(IntelliScore), which is available now.
In patients with lung cancer, the presence or absence of a mutation in EML4-ALK is an indicator of which lung cancer therapies will be most effective. If you have lung cancer, ask your doctor about ExoDx Lung(ALK), which is available now.
In patients with lung cancer, a resistance mutation called T790M can arise as a result of treatment with drugs known as EGFR inhibitors. Early detection of this resistance mutation can ensure patients are being treated with the most effective therapy for their specific cancer. If you are being treated with an EGFR inhibitor for non-small cell lung cancer (NSCLC), ask your doctor about ExoDx Lung(T790M), which will be available in 2017.
In patients with lung cancer, the presence of EGFR activating mutations means that patients are more likely to respond to EGFR inhibitor therapies. The EGFR T790M mutation causes cancer cells to develop resistance to many EGFR inhibitor therapies. If you have lung cancer, ask your doctor about ExoDx Lung(EGFR), which will be available in 2017.
----- These tests were evaluated and its performance characteristics determined by Exosome Diagnostics Inc. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. Exosome Diagnostics is certified under the Clinical Laboratory Improvement Amendments (CLIA) act of 1988 as qualified to perform high complexity clinical testing. CLIA number—22D2093470